In addition, Fbxl10, an H3K4me3-targeted histone demethylase, is actively recruited to the CCL7 promoter region in BC and significantly inhibits its expression, ultimately inducing therapeutic resistance (72). This evidence concerns the gene KDM2B and breast cancer.